We found that the CRPC samples had significantly higher staining of pMED1 than the ADPC and normal prostate samples (Figure 7A and B), suggesting that MED1 phosphorylation increases during prostate cancer progression to the lethal phase. The gene discussed is MED1; the disease is prostate carcinoma.